Nitin Goswami
November 2, 2026
Quick answer: On 26 October 2026, the US FDA approved Talzenna (talazoparib, Pfizer) together with enzalutamide for adults with metastatic prostate cancer that still responds to hormone therapy, or has not yet been treated with it, and that carries an HRR gene mutation. In the TALAPRO-3 trial of 599 men, adding talazoparib cut the risk of the cancer growing on scans, or death, by 52% compared with enzalutamide alone.
A Gene Test Now Matters Earlier in Prostate Cancer
Until this approval, Talzenna with enzalutamide was approved in prostate cancer only after the disease had stopped responding to hormone therapy. The FDA now calls that stage "androgen pathway modulation-resistant" (mAPMR).
The new approval moves it earlier, to men whose cancer has spread but is still hormone-sensitive. The FDA's term is "androgen pathway modulation-naïve or -sensitive" (mAPMN/S). For these men, a genetic test on the tumour or a blood sample can now open up a targeted tablet much sooner. In India, a doctor can request Talzenna for a patient through a regulated Named Patient Program import.
Talzenna Approval at a Glance
| Medicine | Talzenna (talazoparib), Pfizer Inc. |
| FDA decision | Approved 26 October 2026, with priority review |
| Who it is for | Adults with metastatic, hormone-naïve or hormone-sensitive prostate cancer with an HRR gene mutation found by an FDA-authorised test |
| Taken with | Enzalutamide, plus ongoing hormone therapy (a GnRH analogue) or after surgical removal of both testicles |
| Dose | 0.5 mg capsule by mouth once a day, with or without food |
| Main trial | TALAPRO-3 (NCT04821622), 599 patients |
What "HRR Gene Mutation" Means
HRR stands for homologous recombination repair. It is one of the ways a cell fixes breaks in its DNA. Some prostate cancers carry a faulty copy of an HRR gene, so they already struggle to repair themselves.
Talazoparib is a PARP inhibitor. It blocks a second repair route, and a cancer cell that has lost both routes tends to die. That's why the medicine is only for men whose test shows one of these 12 genes is affected:
- BRCA1, BRCA2, ATM, ATR, CDK12, CHEK2
- FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C
The FDA has already approved the FoundationOne CDx (tumour tissue) and FoundationOne Liquid CDx (blood) tests as companion tests for this use.
For storage, strengths and the import steps, see the Talzenna medicine page.
What the TALAPRO-3 Trial Found
TALAPRO-3 was a double-blind trial. All 599 men took enzalutamide every day and stayed on hormone therapy. Half also took talazoparib, and half took a placebo.
- With talazoparib, the median time before the cancer grew on scans (radiographic progression-free survival) had not yet been reached
- With placebo, it was 45.8 months
- Hazard ratio 0.48: a 52% lower risk of scan progression or death
- Overall survival data were still immature at the time of the analysis, so it is too early to say how much longer men live
Side Effects and Warnings
Most common
In the prostate cancer safety data, the most common problems were low blood counts (low haemoglobin in 86%, low neutrophils in 68%, low platelets in 54%), tiredness (48%), back pain, poor appetite and nausea.
Warnings in the prescribing information
- Myelodysplastic syndrome or acute myeloid leukaemia, rare but serious bone marrow cancers
- Low blood counts, so blood tests are needed every month during treatment
- Harm to an unborn baby
Tell your doctor about weakness, fever, frequent infections, easy bruising or blood in the urine or stool.
Prostate Cancer in India
According to GLOBOCAN 2024, India saw 40,071 new prostate cancer cases and 17,018 deaths in a year. It is the 5th most common cancer in Indian men. Doctors and families looking for other targeted cancer medicines can browse our oncology medicines section.
Talzenna's Approvals Now
- Alone, for germline BRCA-mutated, HER2-negative advanced breast cancer
- With enzalutamide, for HRR-mutated metastatic prostate cancer that no longer responds to hormone therapy (mAPMR)
- With enzalutamide, for HRR-mutated metastatic prostate cancer that is hormone-naïve or still hormone-sensitive (mAPMN/S), the new approval
Frequently Asked Questions
Can every man with prostate cancer take Talzenna?
No. It is only for cancer that has spread and carries an HRR gene mutation, found by a validated tumour or blood test. It is always taken together with enzalutamide.
Does this replace hormone therapy?
No. In the trial, every patient stayed on hormone therapy (a GnRH analogue) or had already had both testicles removed. Talazoparib and enzalutamide are added on top.
Is Talzenna available in India?
It can be imported for an individual patient through a regulated Named Patient Program once an oncologist or urologist prescribes it. We handle the import paperwork and delivery.
Why not buy it from any online seller?
Capsules from unregulated sellers can be fake, expired or stored badly, and they often look just like the real product. Through NPP, the medicine comes from authorised sources with proper import documents and batch traceability.
Talk to Our Team
If your doctor has suggested talazoparib with enzalutamide, or you are waiting for HRR gene test results and want to plan ahead, contact our patient access team. We'll explain the documents, timelines and next steps clearly.
Last reviewed: 2 November 2026. This news update is for information only and is not medical advice. Treatment decisions should be made with a qualified oncologist.
References
- US FDA: FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations (26 Oct 2026)
- ClinicalTrials.gov: TALAPRO-3, talazoparib with enzalutamide in men with DDR gene-mutated mCSPC (NCT04821622)
- DailyMed: Talzenna (talazoparib) prescribing information, Pfizer (revised October 2026)
- IARC GLOBOCAN 2024: India fact sheet
